Immune profiles and clinical outcomes between sepsis patients with or without active cancer requiring admission to intensive care units

Background Immunoparalysis was observed in both patients with cancer and sepsis. In cancer patients, Cytotoxic T lymphocyte antigen-4 and programmed cell death protein 1/programmed death-ligand 1 axis are two key components of immunoparalysis. Several emerging therapies against these two axes gained significant clinical benefit. In severe sepsis patients, immunoparalysis was known as compensatory anti-inflammatory response syndrome and this has been suggested as an important cause of death in patients with sepsis. It would be interesting to see if immune status was different in severe sepsis patients with or without active cancer. The aim of this study was to assess the differences in immune profiles, and clinical outcomes between severe sepsis patients with or without cancer admitted to ICU. Methods A combined retrospective and prospective observational study from a cohort of adult sepsis patients admitted to three medical ICUs at Kaohsiung Chang Gung Memorial Hospital in Taiwan between August 2013 and June 2016. Results Of the 2744 patients admitted to the ICU, 532 patients with sepsis were included. Patients were divided into those with or without active cancer according to their medical history. Of the 532 patients, 95 (17.9%) patients had active cancer, and 437 (82.1%) patients had no active cancer history. Patients with active cancer were younger (p = 0.001) and were less likely to have diabetes mellitus (p < 0.001), hypertension (p < 0.001), coronary artery disease (p = 0.004), chronic obstructive pulmonary disease (p = 0.002) or stroke (p = 0.002) compared to patients without active cancer. Patients with active cancer also exhibited higher baseline lactate levels (p = 0.038), and higher baseline plasma interleukin (IL)-10 levels (p = 0.040), higher trend of granulocyte colony-stimulating factor (G-CSF) (p = 0.004) compared to patients without active cancer. The 14-day, 28-day and 90-day mortality rates were higher for patients with active cancer than those without active cancer (P < 0.001 for all intervals). Conclusions Among patients admitted to the ICU with sepsis, those with underling active cancer had higher baseline levels of plasma IL-10, higher trend of G-CSF and higher mortality rate than those without active cancer.

[1]  Jennifer L. Lund,et al.  Decrease in Incidence of Colorectal Cancer Among Individuals 50 Years or Older After Recommendations for Population‐based Screening , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  Borwon Wittayachamnankul,et al.  The role of central venous oxygen saturation, blood lactate, and central venous-to-arterial carbon dioxide partial pressure difference as a goal and prognosis of sepsis treatment. , 2016, Journal of critical care.

[3]  G. Fleuren,et al.  Human Leukocyte Antigen-DR Expression is Significantly Related to an Increased Disease-Free and Disease-Specific Survival in Patients With Cervical Adenocarcinoma , 2016, International Journal of Gynecologic Cancer.

[4]  P. Sasieni,et al.  Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case–control study , 2016, British Journal of Cancer.

[5]  Ping Feng,et al.  Prostate cancer prediction using the random forest algorithm that takes into account transrectal ultrasound findings, age, and serum levels of prostate-specific antigen , 2016, Asian journal of andrology.

[6]  B. Virnig,et al.  Place of Death of Individuals with Terminal Cancer: New Insights from Medicare Hospice Place‐of‐Service Codes , 2016, Journal of the American Geriatrics Society.

[7]  S. H. van der Burg,et al.  Monitoring of the Immune Dysfunction in Cancer Patients , 2016, Vaccines.

[8]  R. Hubbard,et al.  Place of Death in Patients with Lung Cancer: A Retrospective Cohort Study from 2004-2013 , 2016, PloS one.

[9]  M. Mikkelsen,et al.  Neutropenic sepsis is associated with distinct clinical and biological characteristics: a cohort study of severe sepsis , 2016, Critical Care.

[10]  J. Teno,et al.  Family Perspectives on Aggressive Cancer Care Near the End of Life. , 2016, JAMA oncology.

[11]  B. Fox,et al.  Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy , 2016, PloS one.

[12]  Stephanie A Kovalchik,et al.  Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening. , 2016, JAMA.

[13]  F. Hawari,et al.  Predictors of ICU Admission in Patients With Cancer and the Related Characteristics and Outcomes: A 5-Year Registry-Based Study , 2016, Critical care medicine.

[14]  M. Weigand,et al.  Sepsis-induced long-term immune paralysis – results of a descriptive, explorative study , 2016, Critical Care.

[15]  Christopher W Seymour,et al.  Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[16]  Appiah-Korang Labi,et al.  Bloodstream infections in patients with malignancies: implications for antibiotic treatment in a Ghanaian tertiary setting , 2015, BMC Research Notes.

[17]  F. Schaper,et al.  Interleukin-6: Biology, signaling and strategies of blockade. , 2015, Cytokine & growth factor reviews.

[18]  S. Elangovan,et al.  Poor Oral Health Linked with Increased Risk of Infectious Complications in Adults with Leukemia. , 2015, Journal of the Massachusetts Dental Society.

[19]  B. Onwuteaka-Philipsen,et al.  International study of the place of death of people with cancer: a population-level comparison of 14 countries across 4 continents using death certificate data , 2015, British Journal of Cancer.

[20]  D. Levy,et al.  STAT3 regulated ARF expression suppresses prostate cancer metastasis , 2015, Nature Communications.

[21]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[22]  E. Loh,et al.  Factors Affecting the Place of Death Among Hospice Home Care Cancer Patients in Taiwan , 2014, The American journal of hospice & palliative care.

[23]  F. Venet,et al.  Monocyte HLA-DR in sepsis: shall we stop following the flow? , 2014, Critical Care.

[24]  R. Hotchkiss,et al.  Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy , 2013, Nature Reviews Immunology.

[25]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[26]  K. Sundar,et al.  Sepsis induced immunosuppression: Implications for secondary infections and complications , 2013, Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine.

[27]  Timothy R Church,et al.  Selection criteria for lung-cancer screening. , 2013, The New England journal of medicine.

[28]  E. Jantunen,et al.  IL-10 combined with procalcitonin improves early prediction of complications of febrile neutropenia in hematological patients. , 2012, Cytokine.

[29]  O. Finn,et al.  Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  D. Haugen,et al.  Preferences for place of death if faced with advanced cancer: a population survey in England, Flanders, Germany, Italy, the Netherlands, Portugal and Spain. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[32]  V. Urbonas,et al.  Increased interleukin-10 levels correlate with bacteremia and sepsis in febrile neutropenia pediatric oncology patients. , 2012, Cytokine.

[33]  M. Potter,et al.  Outcomes and prognostic factors in patients with haematological malignancy admitted to a specialist cancer intensive care unit: a 5 yr study. , 2012, British journal of anaesthesia.

[34]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[35]  Leah E. Mechanic,et al.  Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. , 2011, Journal of the National Cancer Institute.

[36]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[37]  M. Rizvi,et al.  Serum tumor necrosis factor alpha and C-reactive protein in pediatric patients with sepsis and its correlation with microbiologic findings. , 2010, Indian journal of pathology & microbiology.

[38]  J. Ferlay,et al.  Estimates of cancer incidence and mortality in Europe in 2008. , 2010, European journal of cancer.

[39]  J. M. Teles,et al.  Characteristics and outcomes of patients with cancer requiring admission to intensive care units: A prospective multicenter study* , 2010, Critical care medicine.

[40]  C. Sprung,et al.  Characteristics and outcomes of cancer patients in European ICUs , 2009, Critical care.

[41]  D. Angus,et al.  Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. , 2008, American journal of respiratory and critical care medicine.

[42]  A. Jemal,et al.  Cancer mortality in the United States by education level and race. , 2007, Journal of the National Cancer Institute.

[43]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[44]  Mitchell M. Levy,et al.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference , 2003, Intensive Care Medicine.

[45]  W. V. van Son,et al.  Low HLA-DR expression on monocytes as a prognostic marker for bacterial sepsis after liver transplantation. , 1997, Transplantation.

[46]  R. Bone,et al.  Plasma Cytokine and Endotoxin Levels Correlate with Survival in Patients with the Sepsis Syndrome , 1993, Annals of Internal Medicine.

[47]  D. Levy,et al.  STAT3 regulated ARF expression suppresses prostate cancer metastasis , 2015, Nature Communications.

[48]  K. Chow,et al.  Singapore cancer trends in the last decade. , 2012, Singapore medical journal.

[49]  K. Chow,et al.  Successful maternal-foetal outcome using nitric oxide and sildenafil in pulmonary hypertension with atrial septal defect and HIV infection. , 2012 .

[50]  F. Venet,et al.  Monitoring Immune Dysfunctions in the Septic Patient: A New Skin for the Old Ceremony , 2008, Molecular medicine.

[51]  G. Lyman,et al.  Colony stimulating factors for chemotherapy induced febrile neutropenia. , 2003, The Cochrane database of systematic reviews.